Pharmaceutical - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

201 to 225 of 405 results

Drug developed by UCSF researcher continues to show promise in type 1 diabetes

11-08-2013

Teplizumab, an experimental drug designed to block the advance of type 1 diabetes in its earliest stages…

DiabetesEli LillyPharmaceuticalResearchteplizumab

Novo Nordisk first-half boosted by Victoza and modern insulins

08-08-2013

Danish insulin giant Novo Nordisk (NOV: N) posted second quarter 2013, showing that earnings before interest…

DiabetesFinancialNovo NordiskPharmaceutical

US PDUFA for GSK diabetes drug delayed

03-08-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) revealed on Friday (August 2) that the US Prescription Drug…

albiglutideDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Boehringer Ingelheim and Eli Lilly launch linagliptin trial

01-08-2013

German family-owned drug major Boehringer Ingelheim and US pharma major Eli Lilly (NYSE: LLY) have enrolled…

Boehringer IngelheimDiabetesEli LillyEuropelinagliptinPharmaceuticalResearch

Takeda gains Chinese approval for diabetes drug

31-07-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502), says that the China Food and Drug Administration…

Asia-PacificDiabetesNesinaPharmaceuticalRegulationSanofiTakeda Pharmaceuticals

Adocia re-acquires exclusive rights to insulin analog from US drug major

30-07-2013

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY)…

AdociaBiotechnologyDiabetesEli LillyLicensingPharmaceutical

Three of Takeda's diabetes therapies get positive opinion from EMA unit

29-07-2013

Japan's largest drugmaker Takeda (TSE: 4502) has received a positive opinion from the European Medicines…

DiabetesEuropeIncresyncPharmaceuticalRegulationTakeda PharmaceuticalsVipdometVipidia

First IQWiG assessment of the established drug market finds advantage for Januvia

15-07-2013

There are hints of a minor added benefit of US drug giant Merck & Co's (NYSE: MRK) Januvia (sitagliptin)…

DiabetesEuropeMerck & CoPharmaceuticalPricingRegulation

Safety issues cause Roche to halt investigation of aleglitazar for diabetes

10-07-2013

Swiss drug major Roche (ROG: SIX) revealed this morning (July 10)that it is terminating the Phase III…

aleglitazarDiabetesPharmaceuticalResearchRoche

Lilly and Boehringer Ingelheim's basal insulin MAA accepted by EMA

08-07-2013

US drug major Eli Lilly (NYSE: LLY) and family-owned German pharma firm Boehringer Ingelheim today (July…

Boehringer IngelheimDiabetesEli LillyLantusNovo NordiskPharmaceuticalSanofiVictoza

High out-of-pocket costs for DPP-IV inhibitors and GLP-1 analogues greatly limit prescribing in Brazil, Mexico and Argentina

03-07-2013

Premium-priced DPP-IV inhibitors and GLP-1 analogues used in the treatment of type 2 diabetes lack nationwide…

DiabetesMarkets & MarketingPharmaceuticalPricingSouth America

More ADA highlights, from Eli Lilly on dulaglutide, J&J on Invokana and GSK on albiglutide

24-06-2013

Continued news from the 73rd Scientific Sessions of the American Diabetes Association being held in Chicago,…

albiglutideDiabetesdulaglutideEli LillyGlaxoSmithKlineInvokanaJohnson & JohnsonLY605541PharmaceuticalResearch

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk

21-06-2013

German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA

20-06-2013

Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says that its new diabetes products Nesina…

DiabetesKazanoMarkets & MarketingNesinaNorth AmericaOseniPharmaceuticalTakeda Pharmaceuticals

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds

20-06-2013

Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

Negative US patent ruling for Novo Nordisk on Prandin

19-06-2013

Denmark-based insulin giant Novo Nordisk (NOV: N) says that the US Court of Appeals for the Federal Circuit…

DiabetesGenericsLegalNovo NordiskPatentsPharmaceuticalPrandin

201 to 225 of 405 results

Back to top